Holen Sie sich die Stockscreener-App
1.8798
2.19%
0.0498
Schlusskurs vom Vortag:
$1.83
Offen:
$1.85
24-Stunden-Volumen:
77,294
Relative Volume:
0.20
Marktkapitalisierung:
$117.85M
Einnahmen:
$13.86M
Nettoeinkommen (Verlust:
$-79.62M
KGV:
-1.4646
EPS:
-1.2835
Netto-Cashflow:
$-63.51M
1W Leistung:
+12.65%
1M Leistung:
+28.97%
6M Leistung:
-53.71%
1J Leistung:
+74.77%
1-Tages-Spanne:
$1.82
$1.90
1-Wochen-Bereich:
$1.62
$1.955
52-Wochen-Spanne:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.875 | 115.03M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
427.16 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.40 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
810.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.94 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.78 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - MSN
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7% - MarketBeat
Pyxis Oncology (PYXS) Management Strategy | Pyxis Oncology posts 15.6% EPS beat, no revenueNet Margin - Newser
Pyxis Oncology, Inc. Files Amended 8-K/A Report for 2026 with SEC – Company Details, Address, and Nasdaq Listing - Minichart
[ARS] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology (NASDAQ: PYXS) details 2026 vote on directors and auditor - Stock Titan
Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan
PYXS Pyxis Oncology beats Q4 2025 loss estimates, but shares shed 2.35 percent amid weak investor reaction.EBIT Margin - Newser
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
PYXS Pyxis Oncology Q4 2025 narrower than expected per share loss sparks double digit share price jump today.Expert Stock Picks - Newser
PYXS Stock: Analyzing Pyxis Oncology's Market Performance - Bitget
Pyxis Oncology (PYXS) Cantor Global Healthcare Conference 2025 Summary - Quartr
Pyxis Oncology (PYXS) Registration Filing Summary - Quartr
Pyxis Oncology (PYXS) H.C. Wainwright 26th Annual Global Investment Conference summary - Quartr
Pyxis Oncology (PYXS) Proxy Filing Summary - Quartr
Pyxis Oncology (PYXS) Leerink Global Healthcare Conference 2025 Summary - Quartr
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pyxis presents preclinical data on MICVO in head and neck cancer - Investing.com Australia
Pyxis presents preclinical data on MICVO in head and neck cancer By Investing.com - Investing.com South Africa
Pyxis Oncology to Present New Preclinical Data Showing - GlobeNewswire
Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
PYXS | Pyxis Oncology, Inc. Common Insider Trading - Quiver Quantitative
Growth Value: Will Pyxis Oncology Inc stock benefit from M ARate Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Stock Recap: Can Pyxis Oncology Inc benefit from deglobalization2026 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
Price Action: Is Pyxis Oncology Inc part of any major index2026 Reactions & Low Drawdown Momentum Ideas - baoquankhu1.vn
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69%Stock Entry Points - Newser
Trade Report: Can Pyxis Oncology Inc expand its profit marginsCPI Data & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03%Continuation Signals - Newser
Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - MarketBeat
PYXS Technical Analysis & Stock Price Forecast - Intellectia AI
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst - The Globe and Mail
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
HC Wainwright Raises Earnings Estimates for Pyxis Oncology - Defense World
Stock Report: Can Pyxis Oncology Inc expand its profit marginsDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
HC Wainwright Expects Increased Earnings for Pyxis Oncology - Defense World
Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia
Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan
Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com UK
Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - stocktitan.net
Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - stocktitan.net
Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan
[Form 4] Pyxis Oncology, Inc. Insider Trading Activity - Stock Titan
Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):